Outcome Of Abigail Alliance Case May Be Moot Due To Marketplace Issues
Executive Summary
Regardless of whether a federal appeals court determines that patients have a fundamental right to experimental therapy, it appears a host of potential problems in the marketplace will stymie increased access to such therapies in practice
You may also be interested in...
FDA Can Expand Access To Experimental Drugs, Without Compromising Trials
FDA would be able to maintain the integrity of rigorous clinical trials and permit increased access to experimental drugs through the use of better science, according to former FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb
FDA Can Expand Access To Experimental Drugs, Without Compromising Trials
FDA would be able to maintain the integrity of rigorous clinical trials and permit increased access to experimental drugs through the use of better science, according to former FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb
Clinical Trials Can Charge For Using Competitor Drugs Under FDA Proposed Rule
Clinical trial sponsors are permitted to charge for approved drugs obtained from competitors while conducting a clinical study evaluating an investigational drug under an FDA proposed rule